Chromosomal translocations in cancer and their relevance for therapy

Current Opinion in Oncology

Volumn 18, Issue 1, 2006, Pages 62-68

  Taki, Tomohiko ^a   Taniwaki, Masafumi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Chromosomal translocation; Fusion gene; Mutation; Tyrosine kinase

Indexed keywords

JANUS KINASE 2; NOTCH1 RECEPTOR; NPM PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

CANCER; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; DISEASE COURSE; FUSION GENE; GENE IDENTIFICATION; GENE MUTATION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; MUTATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; NEOPLASMS; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC;

EID: 33646674254     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000198972.69541.04     Document Type: Review

References (46)

1. Graux C, Cools J, Melotte C, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004; 36:1084-1089. Important discovery of a fusion gene on episomal amplification as a novel mechanism of gene rearrangement.
2. De Keersmaecker K, Graux C, Odero MD, et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood 2005; 105:4849-4852.
3. Przybylski GK, Dik WA, Wanzeck J, et al. Disruption of the BCL11B gene through inv(14)(q11.2q32.31) results in the expression of BCL11B-TRDC fusion transcripts and is associated with the absence of wild-type BCL11B transcripts in T-ALL. Leukemia 2005; 19:201-208.
4. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306:269-271. This paper represents that the NOTCH1 is highly mutated in T-ALL, and not only rarely rearranged by chromosomal translocation, and that the altered NOTCH1 could be a potential target for novel therapy.
5. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991; 66:649-661.
6. Grand FH, Burgstaller S, Kuhr T, et al. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res 2004; 64:7216-7219.
7. Levine RL, Wadleigh M, Sternberg DW, et al. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia 2005; 19:27-30.
8. Reiter A, Walz C, Watmore A, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005; 65:2662-2667.
9. Griesinger F, Hennig H, Hillmer F, et al. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 2005; 44:329-333.
10. •].
11. •].
12. •].
13. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387-397. These four papers first represent that the JAK2 is frequently activated by mutation in polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis, and not only by chromosomal translocation in other MPDs.
14. Belloni E, Trubia M, Gasparini P, et al. 8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes. Genes Chromosomes Cancer 2005; 42:320-325.
15. Walz C, Chase A, Schoch C, et al. The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. Leukemia 2005; 19:1005-1009.
16. Chen J, Deangelo DJ, Kutok JL, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A 2004; 101:14479-14484. This study demonstrates the clinical efficacy of the protein tyrosine kinase inhibitor, PKC412, for a patient with MPD having ZNF198-FGFR1 fusion gene.
17. Chen J, Lee BH, Williams IR, et al. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 2005; Aug 8. [Epub ahead of print]
18. Nakamura F, Nakamura Y, Maki K, et al. Cloning and characterization of the novel chimeric gene TEL/PTPRR in acute myelogenous leukemia with inv(12)(p13q13). Cancer Res 2005; 65:6612-6621. The authors were the first to discover PTP as a fusion partner in cancer. Not only protein tyrosine kinases, but also PTPs are good candidates for fusion partners as a result of chromosomal translocations in cancer and thus potential therapeutic targets.
19. Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003; 34:148-150.
20. Wang Z, Shen D, Parsons DW, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004; 304:1164-1166.
21. Nanri T, Matsuno N, Kawakita T, et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia 2005; 19:1361-1366. This study demonstrates that the mutations in the protein tyrosine kinases constitute significant prognostic factors for acute myeloid leukemia with t(8;21) which was identified as a better prognostic factor.
22. Wang YY, Zhou GB, Yin T, et al. AML1-ETO and C-KIT mutation/ overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A 2005; 102:1104-1109. This paper demonstrates that the mutations in the protein tyrosine kinases in acute myeloid leukemia with t(8;21) is a potential target for treatment by imatinib.
23. Taketani T, Taki T, Sugita K, et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 2004; 103:1085-1088.
24. Armstrong SA, Mabon ME, Silverman LB, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004; 103:3544-3546.
25. Ono R, Nakajima H, Ozaki K, et al. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J Clin Invest 2005; 115:919-929. This study demonstrated that direct evidence for a multi-step leukemogenesis mediated by MLL fusion proteins and activated FLT3 using mice model.
26. •].
27. Brown P, Levis M, Shurtleff S, et al. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 2005; 105:812-820. These two studies demonstrated that targeting FLT3 represents a potentially effective therapy for childhood acute lymphoblastic leukemia which has a poor clinical outcome when treated with conventional regimens.
28. Hashii Y, Kim JY, Sawada A, et al. A novel partner gene CIP29 containing a SAP domain with MLL identified in infantile myelomonocytic leukemia. Leukemia 2004; 18:1546-1548.
29. Fu JF, Hsu HC, Shih LY. MLL is fused to EB1 (MAPRE1), which encodes a microtubule-associated protein, in a patient with acute lymphoblastic leukemia. Genes Chromosomes Cancer 2005; 43:206-210.
30. Taki T, Akiyama M, Saito S, et al. The MYO1F, unconventional myosin type 1F, gene is fused to MLL in infant acute monocytic leukemia with a complex translocation involving chromosomes 7, 11 19 and 22. Oncogene 2005; 24:5191-5197.
31. Meyer C, Schneider B, Reichel M, et al. Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci U S A 2005; 102:449-454. It is generally difficult to identify unknown fusion genes. This study established a novel method for identifying an unknown fusion partner of MLL, which was used for the successful identification of four previously unknown genes.
32. Gervais C, Mauvieux L, Perrusson N, et al. A new translocation t(9;11)(q34;p15) fuses NUP98 to a novel homeobox partner gene, PRRX2, in a therapy-related acute myeloid leukemia. Leukemia 2005; 19:145-148.
33. Chan EM, Comer EM, Brown FC, et al. AML1-FOG2 fusion protein in myelodysplasia. Blood 2005; 105:4523-4526.
34. Hosoya N, Qiao Y, Hangaishi A, et al. Identification of a SRC-like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying a t(6;12)(q21;p13) translocation. Genes Chromosomes Cancer 2005; 42:269-279.
35. Yamaguchi S, Yamazaki Y, Ishikawa Y, et al. EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22)(p21;q12). Genes Chromosomes Cancer 2005; 43:217-222.
36. Wachtel M, Dettling M, Koscielniak E, et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 2004; 64:5539-5545. This is the first report that a possible case with unknown fusion gene was expected by the gene expression profiling data and that a novel fusion gene was actually identified in the case.
37. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352:254-266. This paper represents that the NPM is highly mutated in AML with normal karyotype and that this mutation could be a novel prognostic factor and therapeutic target.
38. Ross ME, Mahfouz R, Onciu M, et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 2004; 104:3679-3687.
39. Andersson A, Eden P, Lindgren D, et al. Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations. Leukemia 2005; 19:1042-1050.
40. Haferlach T, Kohlmann A, Schnittger S, et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood 2005; 106:1189-1198.
41. Haferlach T, Kohlmann A, Schnittger S, et al. AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes. Genes Chromosomes Cancer 2005; 43:113-127.
42. Vey N, Mozziconacci MJ, Groulet-Martinec A, et al. Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. Oncogene 2004; 23:9381-9391.
43. Soda Y, Tani K, Bai Y, et al. A novel maxizyme vector targeting a bcr-abl fusion gene induced specific cell death in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2004; 104:356-363.
44. Srinivasan RS, Nesbit JB, Marrero L, et al. The synthetic peptide PFWT disrupts AF4-AF9 protein complexes and induces apoptosis in t(4;11) leukemia cells. Leukemia 2004; 18:1364-1372.
45. Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11:71-76.
46. Weisberg E, Catley L, Kujawa J, et al. Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia 2004; 18:1951-1963.